

## Cell and gene therapy solutions

## Advancing cell and gene therapy drug development

Emerging technologies have driven cell and gene therapies to the forefront of healthcare, addressing a growing number of disease conditions including rare diseases with unmet medical needs.

CGT trials are long, incredibly complex, and riddled with unknowns, that is why advancing development in these areas requires special expertise and the ability to tailor services across all stages of drug development.

We have deep experience partnering with clients to advance development of their cell and gene therapy trials across numerous indications and all development phases.

## Extensive experience in oncology and hematology cell therapy

Our relevant experience over the past 5 years



**598** oncology studies  
**102,000+** patients  
**22,000+** sites



**83** hematology studies  
**11,000+** patients  
**3,500+** sites



**167** I/O studies  
**33,000+** patients  
**8,000+** sites



**137** CGT studies  
including adoptive cell  
therapy studies

Our cell and gene therapy experience

**200+**

projects  
spanning  
all stages of  
development

**100%**

of marketed  
transformative  
advanced  
therapies support

**74+**

successful  
clinical trial  
submissions

Supported 17 of the top 20 top-selling drugs and one of the most published HEOR organizations in the world

## Experienced cross functional teams support nearly every stage of development for advanced therapies



Product development and  
regulatory strategy



Early phase through  
post-approval solutions



Cross-therapeutic expertise



Global site and patient access



CGT specialized laboratory support



Partnerships with CGT therapy  
logistics vendors



CGT logistics coordinator team



Market access, real-world  
evidence and value assessment



Learn more about how we can move your cell and  
gene therapy clinical development program forward.

Learn more at [ppd.com](https://ppd.com)

ppd